A. Financial Results Approval
The Board approved:
1. The Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026
2. Limited Review Report on the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026
B. Annual General Meeting and Record Date
- The 48th Annual General Meeting will be held on Friday, September 11, 2026 at 2:00 P.M. at Mumbai through video-conferencing/other audiovisual means
- The proceedings shall be deemed to be conducted at the Corporate Office: Glenmark House, B D Sawant Marg, Off Western Express Highway, Andheri (E), Mumbai 400 099
- The record date for determining dividend entitlement for FY ended March 31, 2026 shall be Monday, August 31, 2026
C. Amendments to Policies
The Board approved amendments/review of the following policies:
- Policy on Related Party Transactions and its Materiality
- Policy on Determination of Materiality for Disclosures
- Insider Trading Policy
- Dividend Distribution Policy
- Nomination and Remuneration Policy
The revised policies shall be uploaded on the company's website.
D. Reconstitution of Risk Management Committee
The Board approved reconstitution of the Risk Management Committee effective August 01, 2026:
- Ms. Patricia Andrews appointed as Chairperson
- Mr. Glenn Saldanha, Mr. Anurag Mantri and Mr. Dipankar Bhattacharjee as Members
Financial Results Highlights
Standalone Financial Results (Q1 FY27)
- Total Income: ₹25,504.04 million
- Total Expenses: ₹19,073.02 million
- Profit before exceptional items and tax: ₹6,431.02 million
- Exceptional items gain: ₹2,230.00 million (from transfer of Nebulizer brands to Glenmark Healthcare Limited)
- Profit before tax: ₹8,661.02 million
- Profit after tax: ₹7,356.37 million
- Basic EPS: ₹26.07
- Diluted EPS: ₹26.06
Consolidated Financial Results (Q1 FY27)
- Revenue from operations: ₹40,184.83 million
- Other income: ₹657.64 million
- Total income: ₹40,842.47 million
- Total expenses: ₹34,408.58 million
- Profit before exceptional items and tax: ₹6,433.89 million
- Profit before tax: ₹6,433.89 million
- Profit after tax: ₹4,828.28 million
- Profit attributable to owners: ₹4,829.24 million
- Basic EPS: ₹17.11
- Diluted EPS: ₹17.11
Exceptional Items Details
Q1 FY26 Standalone Exceptional Items:
During Q1 FY26, the Board approved transfer of Nebulizer brands and intellectual property portfolio to Glenmark Healthcare Limited (wholly owned subsidiary) for cash consideration of ₹2,230 million, recognized as exceptional gain.
FY26 Standalone and Consolidated Exceptional Items:
- The company and its subsidiary were named in multiple antitrust and consumer protection lawsuits in Eastern District of Pennsylvania, U.S.
- Glenmark agreed to settle with putative direct purchaser class and state attorney general for estimated ₹3,232.32 million and ₹2,780.70 million respectively
- On November 14, 2025, settled with United Healthcare Services, Inc. for ₹976 million
- Other exceptional items include: provision on certain inventories (₹5,901 million), receivables and other current assets (₹4,958.32 million), impairment of property, plant and equipment (₹2,278.91 million), and legal costs (₹1,394.68 million)
- Impact of New Labour Codes: recognized ₹1,138.91 million (consolidated) and ₹1,130.73 million (standalone) towards employee benefits
Other Key Information
- The financial results were prepared in accordance with Ind AS 34
- The results were reviewed by Audit Committee and approved by Board on July 31, 2026
- Subjected to limited review by statutory auditors (Walker Chandiok & Co LLP) who expressed unmodified review conclusion
- The company has one reportable segment: Pharmaceuticals
- As of June 30, 2026, 131,881 ESOP options were outstanding under Employee Stock Options Scheme 2016
- The company has 43 subsidiaries as listed in Annexure A
- Previous period figures have been re-grouped/re-classified for comparability
Auditor's Review
Walker Chandiok & Co LLP conducted limited review and expressed unmodified conclusion on both standalone and consolidated financial results. The review relied on reports from other auditors for 39 subsidiaries representing total revenues of ₹27,175.01 million and net loss of ₹868.27 million for Q1 FY27.
Board Meeting Timing
The Board Meeting commenced at 04:00 p.m. and concluded at 06:20 p.m. on July 31, 2026.
This intimation will be uploaded on the company's website (www.glenmarkpharma.com) and extracts published in newspapers as per Listing Regulations.